JP2010501519A5 - - Google Patents

Download PDF

Info

Publication number
JP2010501519A5
JP2010501519A5 JP2009525046A JP2009525046A JP2010501519A5 JP 2010501519 A5 JP2010501519 A5 JP 2010501519A5 JP 2009525046 A JP2009525046 A JP 2009525046A JP 2009525046 A JP2009525046 A JP 2009525046A JP 2010501519 A5 JP2010501519 A5 JP 2010501519A5
Authority
JP
Japan
Prior art keywords
compound according
methyl
oxazol
azabicyclo
triazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009525046A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010501519A (ja
JP5315244B2 (ja
Filing date
Publication date
Priority claimed from GBGB0616574.0A external-priority patent/GB0616574D0/en
Application filed filed Critical
Publication of JP2010501519A publication Critical patent/JP2010501519A/ja
Publication of JP2010501519A5 publication Critical patent/JP2010501519A5/ja
Application granted granted Critical
Publication of JP5315244B2 publication Critical patent/JP5315244B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009525046A 2006-08-21 2007-08-20 アザビシクロヘキサン誘導体の使用 Expired - Fee Related JP5315244B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0616574.0 2006-08-21
GBGB0616574.0A GB0616574D0 (en) 2006-08-21 2006-08-21 Compounds
PCT/EP2007/058636 WO2008022994A1 (en) 2006-08-21 2007-08-20 Use of azabicyclo hexane derivatives

Publications (3)

Publication Number Publication Date
JP2010501519A JP2010501519A (ja) 2010-01-21
JP2010501519A5 true JP2010501519A5 (enExample) 2010-10-07
JP5315244B2 JP5315244B2 (ja) 2013-10-16

Family

ID=37081324

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009525046A Expired - Fee Related JP5315244B2 (ja) 2006-08-21 2007-08-20 アザビシクロヘキサン誘導体の使用

Country Status (22)

Country Link
US (1) US20080058398A1 (enExample)
EP (1) EP2054054A1 (enExample)
JP (1) JP5315244B2 (enExample)
KR (1) KR101495362B1 (enExample)
CN (1) CN101528221B (enExample)
AR (1) AR062471A1 (enExample)
AU (1) AU2007287527B2 (enExample)
BR (1) BRPI0716454A2 (enExample)
CA (1) CA2661437A1 (enExample)
CL (1) CL2007002422A1 (enExample)
CO (1) CO6150139A2 (enExample)
CR (1) CR10638A (enExample)
EA (1) EA017917B1 (enExample)
GB (1) GB0616574D0 (enExample)
IL (1) IL196976A0 (enExample)
MA (1) MA30672B1 (enExample)
MX (1) MX2009001941A (enExample)
NO (1) NO20090834L (enExample)
PE (1) PE20080609A1 (enExample)
TW (1) TW200825074A (enExample)
WO (1) WO2008022994A1 (enExample)
ZA (1) ZA200900886B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE451364T1 (de) * 2004-02-23 2009-12-15 Glaxo Group Ltd Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate
GB0507601D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507602D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0512099D0 (en) * 2005-06-14 2005-07-20 Glaxo Group Ltd Compounds
ATE484502T1 (de) * 2005-06-14 2010-10-15 Glaxo Group Ltd Neue verbindungen
GB0517187D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517191D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517193D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use
GB0517175D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
US7799815B2 (en) * 2005-08-22 2010-09-21 Glaxo Group Limited Triazole derivatives as modulators of dopamine D3 receptors
JP5189076B2 (ja) * 2006-04-03 2013-04-24 グラクソ グループ リミテッド ドーパミンd3受容体のモジュレーターとしてのアザビシクロ[3.1.0]ヘキシル誘導体
DE602007012531D1 (de) * 2006-04-03 2011-03-31 Glaxo Group Ltd Azabicycloä3.1.0ühexanderivate als modulatoren von dopamin-d3-rezeptoren
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
EP2167083B1 (en) * 2007-06-06 2015-10-28 Euthymics Bioscience, Inc. 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
JP7250405B2 (ja) 2018-01-26 2023-04-03 塩野義製薬株式会社 ドーパミンd3受容体拮抗作用を有する環式化合物
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
AR127055A1 (es) 2021-09-14 2023-12-13 Lilly Co Eli Sales agonistas de sstr4

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4260941B2 (ja) * 1998-11-09 2009-04-30 株式会社片山製薬所 アゼチジン−3−オール
WO2000055131A1 (en) * 1999-03-15 2000-09-21 Novo Nordisk A/S New salt of (2r,3r,4r)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
GB0019228D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
ATE451364T1 (de) * 2004-02-23 2009-12-15 Glaxo Group Ltd Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate
SE526837C2 (sv) * 2004-02-24 2005-11-08 Kongsberg Automotive Asa Växelspakstransmission
AU2005267579A1 (en) * 2004-06-30 2006-02-02 Eli Lilly And Company 1 (indole-6-carbonyl-D-phenylglycinyl) -4- (1-methylpiperidin-4-yl) piperazine D-tartrate
GB0517193D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use

Similar Documents

Publication Publication Date Title
JP2010501519A5 (enExample)
JP2018115191A5 (enExample)
JP2022049005A5 (enExample)
EP3029039B1 (en) Pharmaceutical formulations comprising crystalline forms of (r)-7-chloro-n-(quinuclidin-3-yl)benzo(b)thiophene-2-carboxamide hydrochloride monohydrate
JP2013503134A5 (enExample)
JP2020511467A5 (enExample)
JP2014526549A5 (enExample)
US10100032B2 (en) Crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
JP2014524442A5 (enExample)
JP2012067131A5 (enExample)
RU2016123382A (ru) Твердые формы { [5-(3-хлорфенил)-3-гидроксипиридин-2-карбонил]амино} уксусной кислоты, их композиции и применения
JP2009506014A5 (enExample)
TW202200594A (zh) 一種glp-1受體激動劑的晶型a及其製備方法
JP2018531280A5 (enExample)
HK1225719A1 (en) Pharmaceutical formulations comprising crystalline forms of (r)-7-chloro-n-(quinuclidin-3-yl) benzo(b)thiophene-2-carboxamide hydrochloride monohydrate
JP2013514974A5 (enExample)
CN1372560A (zh) 结晶性1-甲基碳青霉烯化合物
JP2017525717A5 (enExample)
RU2012136148A (ru) Новая кристаллическая форма производного циклопропилбензамида
JP2023500557A (ja) 置換フェニル又はピリジニル部分を有するserd三環化合物の製造方法
JP2013520412A5 (enExample)
RU2451016C2 (ru) Тозилатная соль транс-n-изобутил-3-фтор-3-[3-фтор-4-(пирролидин-1-илметил)фенил]циклобутанкарбоксамида
RU2012136921A (ru) Твердые формы, содержащие производные циклопропиламида
JP5057982B2 (ja) ヒスタミンh3受容体阻害剤、製造及び治療的使用
JP2020512975A5 (enExample)